Study summary · research use only
[Thymogen in the complex treatment of inflammatory diseases of the female genital system]
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This article describes use of the immunomodulating drug thymogen in combined therapy for 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, and purulent tubo-ovarian formations. The authors report that thymogen therapy was associated with normalization of lymphocyte counts and absolute T- and B-lymphocyte counts, increased T-lymphocyte functional activity, and a desensitizing effect, and state that no complications were induced. They describe a marked clinical response and suggest the immunomodulator for combined therapy of inflammatory uterine and adnexal disease.
Abstract
Thymogen, a new immunomodulating drug made in this country, was used in combined therapy of 46 patients with acute endomyometritis, exacerbations of chronic salpingo-oophoritis, purulent tubo-ovarian formations. Thymogen therapy was conducive to normalization of lymphocyte counts, absolute counts of T and B lymphocytes, increase of T lymphocyte functional activity. The drug is characterized by a desensitizing effect and induces no complications. Marked clinical effect recommends the immunomodulator thymogen for combined therapy of patients with inflammatory diseases of the uterus and its appendages.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.